Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

7.010 -0.040 (-0.57%)
Streaming Delayed Price Updated: 2:39 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,497
Open 6.980
Bid (Size) 7.010 (5)
Ask (Size) 7.030 (1)
Prev. Close 7.050
Today's Range 6.860 - 7.159
52wk Range 5.010 - 12.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
CMPS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
-22.02%
-22.02%
1 Month
-8.60%
-8.60%
3 Month
-12.27%
-12.27%
6 Month
-33.99%
-33.99%
1 Year
-22.54%
-22.54%

More News

Read More
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
Should You Buy the Dip on Compass Pathways Stock?
Via The Motley Fool
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Via The Motley Fool
Exposures Product Safety
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What's Going On With MindMed And Psychedelic Stocks?
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
Via The Motley Fool
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
CMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024
Via InvestorPlace
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.